LMNA Genotype

You can have a perfectly normal cholesterol panel, a clean ECG, and still carry a single genetic change that quietly raises your risk of heart failure, dangerous arrhythmias, and sudden cardiac death. Pathogenic variants in the LMNA gene are one of those changes. It is one of the most clinically important genetic causes of dilated cardiomyopathy, and it tends to show up earlier and behave more aggressively than the typical adult-onset version of the disease.

This test reads your DNA at the LMNA (lamin A/C) gene to find inherited variants that disrupt the proteins holding the nucleus of your cells together. It is a one-time test that does not change over your lifetime, and the result can reshape decisions about heart monitoring, when to consider an implantable defibrillator, and which family members should also be screened.

What This Gene Actually Does

LMNA codes for two structural proteins (lamin A and lamin C) that form a fine mesh just underneath the membrane surrounding the nucleus of nearly every differentiated cell in your body. This mesh keeps the nucleus mechanically stable, organizes how DNA is packaged, and helps cells respond to physical stress. When a mutation distorts these proteins, the nucleus becomes fragile, especially in tissues that contract or stretch constantly, like heart muscle, skeletal muscle, and fat.

Because lamins sit at the crossroads of cell architecture and gene regulation, problems with them show up in many different ways. The same gene can cause heart muscle disease in one family, muscular dystrophy in another, severe fat-distribution problems and diabetes in a third, and accelerated aging in a fourth. The cluster of conditions caused by LMNA mutations is collectively called laminopathies.

Dilated Cardiomyopathy and Sudden Cardiac Death

The most clinically urgent reason to know your LMNA status is heart disease. LMNA variants account for roughly 6% of familial dilated cardiomyopathy in commonly cited cohorts, though published estimates range from about 5% to 13% depending on the population studied. Dilated cardiomyopathy is a condition where the heart's main pumping chamber stretches out and weakens. In one large cohort of 795 dilated cardiomyopathy patients, a pathogenic or likely pathogenic LMNA variant was found in 3.1% overall. In a Norwegian cohort, LMNA mutations were present in 6.2% of familial dilated cardiomyopathy cases.

LMNA cardiomyopathy is distinct from the typical adult version. It shows up earlier, progresses faster, and carries a higher risk of dangerous ventricular arrhythmias and the need for heart transplantation. In a meta-analysis pooling more than 8,000 dilated cardiomyopathy patients, LMNA and PLN carriers had a higher prevalence of sudden cardiac death, transplantation, or ventricular arrhythmias than people with sarcomeric gene mutations.

The danger is that sudden cardiac death can be the first sign that anything is wrong. In published cases, the heart can look essentially normal on routine evaluation, and the first event is a life-threatening arrhythmia. Cardiology guidelines have shifted in response. Carrying a high-risk genotype like LMNA is now treated as a reason to consider an implantable cardioverter-defibrillator earlier, independent of how preserved your ejection fraction looks. In a study of 281 patients with monogenetically determined nonhypertrophic cardiomyopathies, genotype-based classification was predictive of sudden cardiac death and major ventricular arrhythmias, while the standard phenotype-based approach was not.

Conduction Disease and Atrial Fibrillation

LMNA also disrupts the electrical wiring of the heart. Carriers often develop conduction block requiring a pacemaker, and atrial fibrillation can be the very first symptom. In a cohort of 101 patients diagnosed with apparent lone atrial fibrillation, rare LMNA variants were found and associated with increased odds of arrhythmic events and abnormal ECG findings. In another series, atrial fibrillation appeared in LMNA carriers at a younger age than in dilated cardiomyopathy patients without the mutation.

The clinical pitfall is real. Patients sometimes receive a pacemaker for unexplained conduction disease, and only later does genetic testing reveal an LMNA variant, prompting an upgrade to a defibrillator that protects against sudden death. Knowing your genotype ahead of time changes the device decision.

Muscle, Metabolic, and Aging Phenotypes

Beyond the heart, LMNA causes a striking range of other syndromes. Striated muscle laminopathies include Emery-Dreifuss muscular dystrophy and limb-girdle muscular dystrophy type 1B, which cause progressive muscle weakness, joint contractures, and frequently coexist with heart involvement. A separate group of variants causes axonal Charcot-Marie-Tooth disease type 2B1, a hereditary peripheral nerve disorder.

Variants clustered around codon 482 of the gene cause familial partial lipodystrophy type 2 (FPLD2), in which fat is lost from the arms, legs, and hips and accumulates in the trunk. This pattern is closely tied to diabetes, very high triglycerides, fatty liver, and early cardiovascular disease. A genotype-phenotype analysis of 77 LMNA carriers found that R482 carriers had lower body mass index, leptin, and fat mass but higher prevalence of diabetes and hypertriglyceridemia, while non-R482 carriers had more arrhythmias and structural heart disease.

At the most severe end of the spectrum, specific LMNA mutations produce progeroid syndromes, characterized by features of accelerated aging, including early vascular disease and premature heart valve calcification. A case series of atypical progeria found novel LMNA variants associated with premature aortic and mitral valve stenosis.

Why Location of the Variant Matters

Not all LMNA variants behave the same. The specific change and where it sits in the gene help predict which organ takes the hit and how aggressive the disease will be. In a study of 718 LMNA carriers, truncating variants (which shorten the protein) were associated with worse arrhythmic outcomes, while missense variants in exons 7 to 12 had better arrhythmic and heart failure outcomes. R482 codon variants point toward the metabolic and lipodystrophy phenotype. Non-R482 variants tend toward arrhythmias and structural heart disease.

This is why a generic answer about LMNA risk is not enough. The exact variant, its predicted effect on the protein, and supporting family history together drive how aggressive monitoring should be.

Carrying the Variant vs Developing Disease

LMNA cardiomyopathy is high penetrance, meaning a large fraction of carriers will eventually develop signs of disease, but it is not 100%. In the Norwegian cohort, asymptomatic young family members carrying the same variant frequently showed early cardiac changes on detailed evaluation. In a UK Biobank-based analysis of about 186,000 middle-aged adults, rare LMNA variants were linked to increased risk of arrhythmia and cardiomyopathy. The takeaway is that a positive result is not a guaranteed diagnosis, but it shifts your lifetime risk upward enough to warrant systematic, ongoing surveillance.

A One-Time Test With Lifetime Implications

Your LMNA genotype does not change. A single test at any point in adulthood gives you your answer for life. The value is not in retesting, it is in acting on the result over the years that follow.

What does need ongoing tracking are the downstream phenotypes. If you test positive, the recommended pattern is regular cardiology follow-up that includes ECG, echocardiography, ambulatory rhythm monitoring, and cardiac MRI. In LMNA carriers, troponin T can also be useful for early disease detection. In a study of 72 young, asymptomatic relatives of LMNA-related dilated cardiomyopathy patients, a high-sensitivity cardiac troponin T level above 5.5 ng/L identified mutation carriers with 86% sensitivity and 93% specificity. NT-proBNP above 150 pg/mL has also been linked to higher risk of malignant ventricular arrhythmia in carriers.

When Genetic Test Results Can Be Misleading

Genetic testing is precise but not all-knowing. A few specific things can lead to a misleading or incomplete result.

• Panel coverage: the assay only detects the variants it is designed to detect. A negative result rules out the variants on the panel, not every possible rare change in LMNA. If clinical suspicion is high, expanded sequencing may be needed.
• Variants of uncertain significance: sometimes a change is found in the gene but its clinical meaning is unclear. One chart-review study of genetic testing found medically impactful differences in interpretation between the laboratory and the ordering clinician in 13.8% of records. A second opinion from a cardiology-focused genetic counselor matters.
• Ancestry-specific variant frequencies: the population-level meaning of a given variant depends on ancestry, which influences how confidently a laboratory can classify it as pathogenic.
• Clinical-grade vs direct-to-consumer testing: results from consumer-grade ancestry tests are not equivalent to clinical sequencing of LMNA and should not be used to make medical decisions.

What to Do With an Unexpected Result

A positive LMNA result is a call to build a workup around it, not a verdict. The decision pathway typically includes a confirmatory sequencing test by a different method if the variant was first identified by a chip-based assay, a referral to a cardiologist with expertise in inherited cardiomyopathies, and a baseline cardiac MRI to look for fibrosis even if your echocardiogram looks normal. Periodic rhythm monitoring is part of standard follow-up because dangerous arrhythmias can precede visible structural changes.

A negative result on a high-quality clinical LMNA panel is reassuring for the variants tested but does not eliminate genetic risk from other cardiomyopathy genes if family history is strong. In that case, a broader cardiomyopathy gene panel may be appropriate. A negative result also has implications for family members, who would not need to be screened for this specific variant.

Any positive result has direct implications for biological relatives. First-degree relatives (parents, siblings, children) each have a 50% chance of carrying the same variant. Cascade testing in the family is one of the highest-yield uses of this test, because it can identify carriers before any symptoms appear and put them into surveillance early.